Monika Pogorzala1, Malgorzata Kubicka1, Beata Rafinska1, Mariusz Wysocki1, Jan Styczynski2. 1. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland. 2. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland jstyczynski@cm.umk.pl.
Abstract
AIM: To analyze the drug-resistance profile at first and subsequent relapse in children with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: A total of 154 pediatric ALL samples were tested for ex vivo chemosensitivity for up to 19 drugs. Their combined drug resistance profile (PVA score) was analyzed. RESULTS: The median relative resistance scores between patients with multiple relapse and those with first relapse considering all drugs was 2.0. The median PVA score at subsequent relapses was 8 vs. 6 at first relapse (p=0.004). Samples from multiple-relapsed ALL were more drug resistant to: prednisolone (>1.9-fold), dexamethasone (>1.5-fold), vincristine (3.1-fold), L-asparaginase (5-fold), mitoxantrone (2.4-fold), cytarabine (4.3-fold), mercaptopurine (2.2-fold), thioguanine (4.8-fold), etoposide (2.6-fold) and melphalan (2.7-fold). Lymphoblasts at multiple relapse were comparably resistant to: daunorubicin, doxorubicin, cyclophosphamide, ifosfamide, busulfan, treosulfan, fludarabine, clofarabine and bortezomib. CONCLUSION: In comparison to first relapse, subsequent relapsed childhood ALL is more ex vivo-resistant to most tested drugs. Copyright
AIM: To analyze the drug-resistance profile at first and subsequent relapse in children with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: A total of 154 pediatric ALL samples were tested for ex vivo chemosensitivity for up to 19 drugs. Their combined drug resistance profile (PVA score) was analyzed. RESULTS: The median relative resistance scores between patients with multiple relapse and those with first relapse considering all drugs was 2.0. The median PVA score at subsequent relapses was 8 vs. 6 at first relapse (p=0.004). Samples from multiple-relapsed ALL were more drug resistant to: prednisolone (>1.9-fold), dexamethasone (>1.5-fold), vincristine (3.1-fold), L-asparaginase (5-fold), mitoxantrone (2.4-fold), cytarabine (4.3-fold), mercaptopurine (2.2-fold), thioguanine (4.8-fold), etoposide (2.6-fold) and melphalan (2.7-fold). Lymphoblasts at multiple relapse were comparably resistant to: daunorubicin, doxorubicin, cyclophosphamide, ifosfamide, busulfan, treosulfan, fludarabine, clofarabine and bortezomib. CONCLUSION: In comparison to first relapse, subsequent relapsed childhood ALL is more ex vivo-resistant to most tested drugs. Copyright
Authors: Werner J Geldenhuys; Rajesh R Nair; Debbie Piktel; Karen H Martin; Laura F Gibson Journal: J Pharmacol Exp Ther Date: 2019-04-22 Impact factor: 4.030
Authors: Rajesh R Nair; Debbie Piktel; Quincy A Hathaway; Stephanie L Rellick; Patrick Thomas; Pushkar Saralkar; Karen H Martin; Werner J Geldenhuys; John M Hollander; Laura F Gibson Journal: Pharm Res Date: 2020-01-27 Impact factor: 4.200
Authors: Ashanti Concepción Uscanga-Palomeque; Kenny Misael Calvillo-Rodríguez; Luis Gómez-Morales; Eva Lardé; Thomas Denèfle; Diana Caballero-Hernández; Hélène Merle-Béral; Santos A Susin; Philippe Karoyan; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla Journal: Cancer Sci Date: 2018-12-14 Impact factor: 6.716
Authors: Abozer Y Elderdery; Badr Alzahrani; Abdulrahim A Alabdulsalam; Siddiqa M A Hamza; Ahmed M E Elkhalifa; Abdulaziz H Alhamidi; Fehaid Alanazi; A Mohamedain; Suresh Kumar Subbiah; Pooi Ling Mok Journal: Bioinorg Chem Appl Date: 2022-09-28 Impact factor: 4.724